How Agaricus blazei Improves Insulin Sensitivity

Agaricus blazei (Royal Sun Mushroom)

20% adiponectin increase

Agaricus blazei supplementation raised plasma adiponectin by 20% in a 12-week double-blind RCT in type 2 diabetics, providing the clearest human evidence for its insulin-sensitizing mechanism.

Hsu et al., Journal of Alternative and Complementary Medicine, 2007

5 pathways

distinct mechanisms through which ABM affects insulin signaling and glucose metabolism

2×

more anti-diabetic activity from enzymatically hydrolyzed oligosaccharides vs. whole beta-glucans

72 patients

in the only published double-blind placebo-controlled human RCT for ABM and insulin resistance

Hsu et al., Journal of Alternative and Complementary Medicine, 2007

View as image ↗

In a 12-week double-blind RCT, 72 adults with type 2 diabetes who were already taking metformin and gliclazide were randomized to add either 1500 mg/day of Agaricus blazei extract or a matching placebo. By the end of the trial, the ABM group showed significantly reduced insulin resistance scores and a 20% increase in plasma adiponectin (a hormone the body uses to regulate insulin response) compared to the placebo group.^[1]

That's the only published human RCT for ABM and insulin sensitivity. The animal and cell-based research fills in the mechanistic picture in substantial detail, identifying at least five distinct pathways through which ABM affects glucose metabolism. This article covers those pathways, what each one does at the biological level, and what evidence supports each. For the full clinical evidence picture, see our article on Agaricus blazei for type 2 diabetes clinical evidence. For the broader context on what this mushroom is, see what is Agaricus blazei.

The five mechanisms through which Agaricus blazei improves insulin sensitivity:

1. Adiponectin upregulation: raises the hormone that improves insulin receptor responsiveness
2. PI3K/Akt/GLUT-4 activation: amplifies the intracellular insulin signaling cascade
3. Alpha-glucosidase inhibition: slows carbohydrate digestion and blunts post-meal glucose spikes
4. Pancreatic lipase inhibition and increased energy expenditure: prevents fat-driven insulin resistance
5. PPARgamma activation: acts on the same nuclear receptor target as some diabetes medications

Adiponectin: The Hormone ABM Raised by 20% in Human Subjects

Adiponectin is a hormone produced by fat cells that does something counterintuitive: it decreases when you gain weight, at the same time your insulin resistance tends to rise. People with type 2 diabetes typically have low adiponectin levels, and raising adiponectin is one of the goals of several diabetes treatments.

The Hsu 2007 RCT found that 12 weeks of ABM supplementation raised plasma adiponectin by approximately 20% in the treatment group versus no change in the placebo group.^[1] The study measured insulin resistance using HOMA-IR, a formula that combines fasting glucose and fasting insulin into a single score reflecting how hard the body is working to keep blood sugar in balance. Higher HOMA-IR means more resistant. The ABM group's HOMA-IR fell significantly.

The mechanistic connection between these two findings is direct: adiponectin activates insulin receptor substrate proteins and enhances downstream signaling from insulin receptors on muscle and fat cells. When adiponectin rises, cells become more responsive to insulin. The insulin levels hadn't changed; the cellular machinery that responds to insulin became more sensitive.

The adiponectin finding is important for another reason: it explains the mechanism in terms of a measurable human biomarker. Most of the remaining ABM insulin data comes from animal models. Hsu 2007's adiponectin measurement bridges animal mechanisms to human physiology. The 20% increase produced a corresponding improvement in insulin resistance scores, confirming that the hormone change was functionally significant, not just a biomarker shift.

PI3K/Akt/GLUT-4: Amplifying the Cellular Insulin Signal

When insulin binds to its receptor on a cell, it triggers a cascade of enzyme activations inside the cell. The key steps are: insulin receptor phosphorylation → IRS (insulin receptor substrate) activation → PI3K (phosphoinositide 3-kinase) activation → Akt kinase phosphorylation → GLUT-4 translocation to the cell membrane.

GLUT-4 is the glucose transporter protein on muscle and fat cells. It sits waiting inside the cell until insulin signals arrive, at which point it moves to the cell surface and opens channels that pull glucose from the bloodstream into the cell. In insulin-resistant individuals, this entire cascade runs inefficiently: the signal gets weaker at each step, fewer GLUT-4 transporters reach the surface, and glucose builds up in the blood instead of entering cells.

Wei and colleagues tested whether ABM supplementation affected this pathway in streptozotocin-induced diabetic rats in 2020.^[2] The results were dose-dependent: higher ABM doses produced greater activation of PI3K and Akt signaling and higher GLUT-4 expression in muscle tissue, along with elevated plasma insulin. In practical terms, the mushroom extract appeared to amplify the insulin signaling cascade that insulin resistance had weakened.

This pathway is the molecular mechanism that likely underlies the HOMA-IR improvement Hsu measured in humans. The Pi3K/Akt pathway is also the target of insulin sensitizers in pharmaceutical development, which makes ABM's activity on this pathway mechanistically meaningful rather than coincidental.

Alpha-Glucosidase Inhibition: Slowing the Post-Meal Glucose Spike

Alpha-glucosidase is an enzyme that lines the small intestine and breaks complex carbohydrates (starches and disaccharides) down into glucose molecules small enough to absorb into the bloodstream. Inhibiting alpha-glucosidase slows this digestion process, spreading glucose entry into the bloodstream over a longer time period and blunting the sharp post-meal spike.

This is the mechanism behind one class of diabetes medications (acarbose, miglitol) and is also one of the ways metformin works. Wei and colleagues tested ABM's alpha-glucosidase inhibitory activity in a 2020 in vitro study using a cell-based glucose uptake model.^[3]

Their results: the ethyl acetate fraction of ABM inhibited alpha-glucosidase and increased glucose uptake by liver cells (HepG2) to a degree comparable to metformin in the same assay. The active compounds responsible included both beta-glucan polysaccharides and isoflavonoids: specifically genistein, genistin, daidzein, and daidzin. These isoflavonoids are more commonly associated with soy but appear to be present in ABM extracts and contribute meaningfully to the glucose-lowering activity.

The "comparable to metformin in vitro" framing requires qualification: in vitro cell assays don't replicate the complexity of human metabolism, and the concentrations tested may not reflect what reaches target tissues after oral consumption. But the finding identifies a specific enzyme target and specific compound classes responsible, which is useful for understanding which extraction methods would capture the active compounds (ethyl acetate fractions, not just aqueous extracts). For more on ABM's bioactive compounds, see Agaricus blazei bioactive compounds: beta-glucans and blazein.

Pancreatic Lipase Inhibition: A Prevention Pathway

The first four mechanisms operate primarily in already-insulin-resistant tissue. Vincent and colleagues documented a fifth mechanism that appears to operate upstream: prevention of the metabolic changes that create insulin resistance in the first place.^[4]

Their 2013 study fed rats a high-fat diet designed to induce obesity and insulin resistance. Rats in the ABM group didn't gain as much weight and didn't develop the expected degree of insulin resistance. The mechanism wasn't appetite suppression. The ABM-treated rats ate the same amount of food as controls. Instead, they showed increased energy expenditure, higher locomotor activity, and reduced pancreatic lipase activity.

Pancreatic lipase is the enzyme that breaks down dietary fat into absorbable fatty acids. Reducing its activity means less dietary fat is absorbed, reducing the caloric and lipid overload that drives visceral fat accumulation, chronic inflammation, and eventually insulin resistance. This is the same mechanism used by orlistat, a weight management medication.

The energy expenditure increase adds a second dimension: the rats were apparently burning more calories at rest and through movement. How exactly ABM increases energy expenditure at the molecular level wasn't fully characterized in this study, but the overall picture is a metabolic shift toward greater fat burning and reduced fat accumulation, both of which protect against the type of insulin resistance associated with obesity.

PPARgamma Activation: A Target ABM Shares With Diabetes Medications

The fifth mechanism is the most pharmacologically interesting. Kundakovic and Kolundzic's 2013 review identified mushroom terpenoids as PPARgamma activators alongside their alpha-glucosidase inhibitory activity.^[5]

PPARgamma (peroxisome proliferator-activated receptor gamma) is a nuclear receptor inside cells that, when activated, changes gene expression programs to improve insulin sensitivity. It's the target of thiazolidinediones, a class of diabetes medications including pioglitazone and the now-withdrawn rosiglitazone. When PPARgamma is activated, cells become better at taking up and using glucose, inflammatory gene programs are downregulated, and adiponectin production from fat cells increases.

The ABM-terpenoid connection to PPARgamma explains the adiponectin result from Hsu 2007 through a different lens: if ABM terpenoids activate PPARgamma in fat cells, and PPARgamma activation upregulates adiponectin production, then the 20% adiponectin rise in the human RCT may have been driven at least partly by this pathway rather than (or in addition to) direct beta-glucan signaling.

This dual activity (alpha-glucosidase inhibition plus PPARgamma activation) means ABM affects two distinct points in the glucose metabolism problem simultaneously: slower glucose entry from the gut, and improved cellular insulin response. Few single plant or fungal compounds accomplish both.

Which Compounds Are Doing the Work

With five distinct mechanisms identified, the natural question is which compounds drive which effects. Huang and colleagues' 2022 comprehensive review and Kim and colleagues' 2005 fractionation study provide the clearest answers.^[7][6]

Beta-glucan polysaccharides are the primary immune-modulating compounds in ABM and contribute to alpha-glucosidase inhibition and probably to adiponectin pathways. But Kim 2005 found something important: enzymatically hydrolyzed ABM oligosaccharides (the shorter-chain breakdown products of beta-glucans, specifically di- and trisaccharides) had approximately twice the anti-diabetic activity of intact beta-glucans in diabetic rats, including anti-hyperglycemic, anti-hypertriglyceridemic, and anti-hypercholesterolemic effects.^[6]

This means the bioavailability of the active fraction matters: a whole mushroom extract with intact polysaccharides may be less potent than a product that has partially hydrolyzed the beta-glucans to release shorter oligosaccharide chains. Most commercial ABM supplements use water or ethanol extraction without enzymatic hydrolysis, which may leave the more potent fraction in a less bioactive form.

Isoflavonoids (genistein, daidzein) contribute to alpha-glucosidase inhibition and show up in the ethyl acetate fraction. Triterpenoids drive PPARgamma activation. Blazein, a steroid compound unique to ABM, has anti-inflammatory and antitumor activity but less specifically studied anti-diabetic activity.

The compound picture is complex enough that extraction method matters significantly for which mechanisms are most active in any given supplement product. For anyone taking ABM for metabolic health alongside prescription medications, the drug interaction profile is equally important to understand, particularly the potential to potentiate hypoglycemic drugs. See our article on Agaricus blazei and drug interactions for the safety context.

ABM shares some of its mechanistic territory with other medicinal mushrooms studied for insulin resistance, particularly Reishi. For a comparison, see Ganoderma lucidum and insulin resistance.

The Bottom Line

Agaricus blazei improves insulin sensitivity through at least five studied mechanisms: adiponectin upregulation, PI3K/Akt/GLUT-4 pathway activation, alpha-glucosidase inhibition, pancreatic lipase inhibition with increased energy expenditure, and PPARgamma activation. The Hsu 2007 RCT in 72 type 2 diabetics provides the only human evidence, with a 20% adiponectin increase and significant HOMA-IR reduction after 12 weeks. The remaining evidence comes from animal models and cell-based studies. Enzymatically hydrolyzed oligosaccharides appear twice as potent as intact beta-glucans in animal models, suggesting that extraction and processing method meaningfully affects bioactivity.

Frequently Asked Questions

How does agaricus blazei reduce insulin resistance?

Agaricus blazei reduces insulin resistance through multiple pathways. In the only human RCT (Hsu 2007, 72 type 2 diabetics), ABM raised plasma adiponectin by 20% and reduced HOMA-IR scores after 12 weeks. Animal studies show it also activates the PI3K/Akt/GLUT-4 signaling cascade (the intracellular pathway that insulin triggers to pull glucose into cells), inhibits alpha-glucosidase (slowing carbohydrate absorption), inhibits pancreatic lipase (reducing fat absorption), and activates PPARgamma (a nuclear receptor that improves insulin sensitivity at the gene expression level).

What is the mechanism of agaricus blazei for insulin?

The most directly measured mechanism in humans is adiponectin upregulation: a 20% increase in plasma adiponectin in type 2 diabetics after 12 weeks (Hsu 2007). Adiponectin improves cellular responsiveness to insulin. At the molecular level, animal studies show ABM activates the PI3K/Akt pathway and upregulates GLUT-4 expression in muscle tissue. GLUT-4 is the protein that physically transports glucose from the bloodstream into cells when insulin signals are present.

Does agaricus blazei increase adiponectin?

Yes. The Hsu 2007 double-blind RCT in 72 type 2 diabetics found that 1500 mg/day of ABM extract for 12 weeks raised plasma adiponectin by approximately 20% compared to placebo. Adiponectin is a hormone produced by fat cells that typically decreases as insulin resistance develops; raising it is associated with improved insulin receptor sensitivity. Hsu's team proposed adiponectin upregulation as the primary mechanism behind the HOMA-IR reduction they observed.

Which compounds in agaricus blazei affect blood sugar?

Multiple compound classes contribute. Beta-glucan polysaccharides are the primary active fraction for most effects. Enzymatically hydrolyzed oligosaccharides (short-chain beta-glucan breakdown products) showed twice the anti-diabetic activity of intact beta-glucans in animal tests (Kim 2005). Isoflavonoids (genistein, genistin, daidzein, daidzin) inhibit alpha-glucosidase at the intestinal level. Triterpenoids activate PPARgamma, a nuclear receptor involved in insulin sensitivity. The ethyl acetate extraction fraction appears to capture the most potent anti-diabetic compounds, including the isoflavonoids.

How does agaricus blazei affect GLUT-4?

GLUT-4 is the glucose transporter protein on muscle and fat cells that insulin activates to move glucose from the bloodstream into cells. Wei 2020 animal studies showed that ABM supplementation activated the PI3K/Akt signaling cascade in a dose-dependent manner in diabetic rats, leading to upregulated GLUT-4 expression in muscle tissue. This means more transporter proteins reach the cell surface when insulin signals are present, improving the efficiency of the cellular response to insulin.

Sources & References

1. 1RTHM-00114·Hsu, Chung-Hua et al. (2007). “The mushroom Agaricus Blazei Murill in combination with metformin and gliclazide improves insulin resistance in type 2 diabetes: a randomized, double-blinded, and placebo-controlled clinical trial..” Journal of alternative and complementary medicine (New York.Study breakdown →PubMed →↩
2. 2RTHM-00663·Wei, Qi et al. (2020). “Enhancement of glucose homeostasis through the PI3K/Akt signaling pathway by dietary with Agaricus blazei Murrill in STZ-induced diabetic rats..” Food science & nutrition.Study breakdown →PubMed →↩
3. 3RTHM-00662·Wei, Qi et al. (2020). “Assessment of antioxidant and antidiabetic properties of Agaricus blazei Murill extracts..” Food science & nutrition.Study breakdown →PubMed →↩
4. 4RTHM-00308·Vincent, Mylène et al. (2013). “Dietary supplementation with Agaricus blazei murill extract prevents diet-induced obesity and insulin resistance in rats..” Obesity (Silver Spring.Study breakdown →PubMed →↩
5. 5RTHM-00294·Kundaković, Tatjana et al. (2013). “Therapeutic properties of mushrooms in managing adverse effects in the metabolic syndrome..” Current topics in medicinal chemistry.Study breakdown →PubMed →↩
6. 6RTHM-00082·Kim, Yea-Woon et al. (2005). “Anti-diabetic activity of beta-glucans and their enzymatically hydrolyzed oligosaccharides from Agaricus blazei..” Biotechnology letters.Study breakdown →PubMed →↩
7. 7RTHM-00765·Huang, Kaiyuan et al. (2022). “Critical review on chemical compositions and health-promoting effects of mushroom Agaricus blazei Murill..” Current research in food science.Study breakdown →PubMed →↩